Compass Pathways Stock News

Shares of COMPASS Pathways plc (NASDAQ:CMPS) rose 3.2% on Monday . The company traded as high as $24.45 and last traded at $24.19. Approximately 9,915 shares changed hands during trading, a decline of 99% from the average daily volume of 722,103 shares. The stock had previously closed at $23.45. CMPS has been the topic of []

London, U.K., Dec. 17, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental hea

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) revealed Friday that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective as of

COMPASS Pathways plc (NASDAQ:CMPS) shares reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $23.00 and last traded at $23.10, with a volume of 963 shares. The stock had previously closed at $23.76. A number of equities analysts have recently issued reports on the company. Zacks Investment []

PALM BEACH, Fla. , Dec. 14, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy - the medically approved use of MDMA, psilocybin, and LSD as a component of elevated psychotherapy programs. A study conducted by Yale on mice determined that one dose of psilocybin immediately increased neural connections in the brains. Doctors believe this helps the brain "reorganize and adapt" to different situations, improving response time. MDMA has recently been designated a breakthrough treatment for post-traumatic stress disorder (PTSD) by the U.S. Food and Drug Administration (FDA), opening the way for its approval within two years. In a study published in Nature Medicine, symptoms of depression were significantly reduced after three doses of MDMA given at monthly intervals.

Morgan Stanley lifted its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 99.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 96,730 shares of the companys stock after purchasing an additional 48,343 shares during the quarter. Morgan Stanley owned about 0.24% of COMPASS []

COMPASS Pathways plc (NASDAQ:CMPS) dropped 7.2% on Monday . The company traded as low as $27.40 and last traded at $27.48. Approximately 22,095 shares changed hands during trading, a decline of 95% from the average daily volume of 481,811 shares. The stock had previously closed at $29.60. Several equities analysts recently issued reports on CMPS […]

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S

COMPASS Pathways plc (NASDAQ:CMPS)s stock price reached a new 52-week low during trading on Friday . The company traded as low as $28.56 and last traded at $29.60, with a volume of 677085 shares trading hands. The stock had previously closed at $31.95. A number of equities research analysts have commented on the company. Roth []

Belvedere Trading LLC grew its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 95.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 39,364 shares of the companys stock after acquiring an additional 19,274 shares during the period. COMPASS Pathways comprises 0.0% of Belvedere []

London, UK - 3 December 2021

As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared

- Positive topline results validated by additional analyses

LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three investor conferences as follows: